-At 12-months, 54% of evaluable patients achieved DORIS remission and 50% of patients achieved CRR-

-All patients discontinued immunosuppressants –

- All but one patient tapered background steroids to ≤5 mg prednisone equivalent per day-

-Rapid reductions in SLEDAI-2K and PGA scores, consistent with autologous alpha beta CAR-T cell therapies-

-Plan to initiate pivotal lupus nephritis trial start-up activities in 4Q/2026; high DORIS remission rate may support expansion of pivotal study to include lupus without nephritis based on regulatory precedent-

-Company to host investor webcast at 8:00am ET today-

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.